

Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants

Anita J. Kumar,¹ Soyoung Kim,^{2,3} Michael T. Hemmer,² Mukta Arora,⁴ Stephen R. Spellman,⁵ Joseph A. Pidala,⁶ Daniel R. Couriel,⁷ Amin M. Alousi,⁸ Mahmoud D. Aljurf,⁹ Jean-Yves Cahn,¹⁰ Mitchell S. Cairo,¹¹ Corey S. Cutler,¹² Shatha Farhan,¹³ Usama Gergis,¹⁴ Gregory A. Hale,¹⁵ Shahrukh K. Hashmi,¹⁶ Yoshihiro Inamoto,¹⁷ Rammurti T. Kamble,¹⁸ Mohamed A. Kharfan-Dabaja,⁶ Margaret L. MacMillan,¹⁹ David I. Marks,²⁰ Hideki Nakasone,²¹ Maxim Norkin,²² Muna Qayed,²³ Olle Ringden,²⁴ Harry C. Schouten,²⁵ Kirk R. Schultz,²⁶ Melhem M. Solh,²⁷ Takanori Teshima,²⁸ Alvaro Urbano-Ispizua,²⁹ Leo F. Verdonck,³⁰ Robert Peter Gale,³¹ Betty K. Hamilton,³² Navneet S. Majhail,³² and Alison W. Loren³³

¹Tufts Medical Center, Boston, MA; ²Center for International Blood and Marrow Transplant Research, Department of Medicine, and ³Institute for Health and Society, Department of Biostatistics, Medical College of Wisconsin, Milwaukee, WI; ⁴Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN; ⁵Center for International Blood and Marrow Transplant Research, National Marrow Donor Program/Be The Match, Minneapolis, MN; ⁶Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ⁷Utah Blood and Marrow Transplant Program, Salt Lake City, UT; ⁸Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; ⁹Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia; ¹⁰Department of Hematology, Centre Hospitalier Universitaire de Grenoble, Grenoble, France; ¹¹Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY; ¹²Center for Hematologic Oncology, Dana-Farber Cancer Institute, Boston, MA; ¹³Henry Ford Hospital Bone Marrow Transplant Program, Wayne State University, Detroit, MI; ¹⁴Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, NY; ¹⁵Department of Hematology/Oncology, Johns Hopkins All Children's Hospital, St. Petersburg, FL; ¹⁶Department of Internal Medicine, Mayo Clinic, Rochester, MN; ¹⁷Fred Hutchinson Cancer Research Center, Seattle, WA; ¹⁸Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX; ¹⁹University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN; ²⁰Adult Bone Marrow Transplant, University Hospitals Bristol National Health Service Trust, Bristol, United Kingdom; ²¹Jichi Medical University, Shimotsuke, Japan; ²²Division of Hematology/Oncology, University Florida College of Medicine, Gainesville, FL; ²³Department of Pediatrics, Emory University School of Medicine, Atlanta, GA; ²⁴Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; ²⁵Department of Hematology, Academische Ziekenhuis, Maastricht, The Netherlands; ²⁶Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia's Children's Hospital, The University of British Columbia, Vancouver, BC, Canada; ²⁷The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA; ²⁸Kyushu University Hospital, Sapporo, Japan; ²⁹Department of Hematology, Hospital Clinic, University of Barcelona, Institut d'investigacions Biomediques August Pi i Sunyer, and Institute of Research Josep Carreras, Barcelona, Spain; ³⁰Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands; ³¹Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, London, United Kingdom; ³²Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; and ³³Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Key Points

- Compared with parous female sibling donors, male URDs confer more aGVHD in all patients and more cGVHD in females.
- There was no difference in survival, relapse, or transplant mortality between recipients of parous female sibling or male URD grafts.

Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors. We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4 acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary outcomes included disease-free survival, transplant-related mortality, and relapse. In 2813 recipients, patients receiving male URD transplants ($n = 1921$) had 1.6 times higher risk of grade 2 to 4 aGVHD ($P < .0001$). For cGVHD, recipient sex was a significant

factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts (relative risk [RR] = 1.43, $P < .0001$), whereas male recipients had similar rates of cGVHD regardless of donor type (RR = 1.09, $P = .23$). Donor type did not significantly affect any other end point. We conclude that when available, parous female siblings are preferred over male URDs.

Introduction

Allogeneic hematopoietic cell transplant (HCT) is a potentially curative but risky therapy for patients with hematologic malignancies. Acute and chronic graft-versus-host disease (aGVHD and cGVHD, respectively) are significant contributors to adverse outcomes including death. To reduce complications from HCT, optimal donor selection is critical. Specific factors influencing donor selection include HLA matching, cytomegalovirus (CMV) serologic status, ABO compatibility, age, sex, and parity (ie, the number of prior pregnancies).¹⁻³ With increasing use of unrelated donors (URDs) for allogeneic HCT, large studies have evaluated outcomes for patients with sibling donor vs URD, with most demonstrating similar long-term survival among the 2 donor groups.⁴⁻¹⁴ However, when given the option of a sibling donor or URD, sibling donors are typically preferred for convenience and possibly to reduce GVHD and to improve survival. Both donor-recipient sex mismatching and the effect of donor parity have been evaluated as possible influences on transplant morbidity and mortality. There is an increased risk of cGVHD (and in some studies, aGVHD) in recipients of grafts from female donors, regardless of recipient sex, although some studies indicate an even greater risk in male recipients, presumably because of female donors' immune response to the H-Y antigen.^{2,3,15-23} Female donors who have a history of pregnancy ("parous females"), may confer more GVHD in all patients^{2,19,21} or, in some studies, only in male recipients.^{3,15,16,18,23} In 2006, a large registry analysis using the Center for International Blood and Marrow Transplant Research (CIBMTR) evaluated the impact of sex and parity on aGVHD and cGVHD after HLA-identical sibling HCT. This study established parity as a risk factor for cGVHD in both male and female recipients from parous female (vs male) sibling donors. It also demonstrated that nulliparous female sibling donors confer an increased risk of cGVHD to male recipients.²¹

Cost and delay are important considerations when choosing a donor, and often transplant physicians choose sibling donors regardless of sex or parity because of these concerns. However, all patients who may be transplant candidates are now urged to have HLA typing performed and siblings typed as early as possible in the treatment course. Hence, we anticipate that delays may become shorter or less frequently encountered when using URDs. Furthermore, we hypothesized that if it were shown that recipients of male URD grafts had substantially better outcomes, a clinician may decide that some additional cost and/or delay might be worthwhile. Given the well-documented increased risk of aGVHD and cGVHD associated with parous female sibling donors, we sought to understand whether choosing a male URD would be a preferred strategy for donor selection.

Methods

Data source

The data source for the study was the registry of the CIBMTR, a collaboration between the National Marrow Donor Program and the Medical College of Wisconsin: a voluntary working group of >500 transplantation centers that collaborates to share patient data and conduct scientific studies. The quality and compliance of data submission are monitored by computerized checks for errors, physician reviews, and on-site audits. Observational studies conducted by CIBMTR are performed with informed consent in accordance with the Declaration of Helsinki and in compliance with Health Insurance Portability and Accountability Act regulations as determined by the National Marrow Donor Program and Medical College of Wisconsin Institutional review board.

Patient selection

Adult patients who reported to the CIBMTR with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) and who underwent a T-cell replete myeloablative, nonmyeloablative, or reduced intensity conditioning HCT from an HLA-identical parous female sibling or matched male URD between 2000 and 2012 were included in the study. URD HLA match was defined as a high-resolution match at HLA-A, B, C, and DRB1 as previously described.²⁴ Donor parity was captured on CIBMTR collection forms prior to HCT. Patients were at least 25 years old at the time of transplant to allow a greater likelihood that sibling donors had the opportunity to be parous and to reduce the likelihood of missing parity status in donors of younger ages. Recipients of both peripheral blood stem cell (PBSC) and bone marrow (BM) grafts were included.

Study design and end points

This was a retrospective cohort study examining outcomes among patients who received HCTs from parous female sibling donors compared with male URDs. The primary outcomes were incidence of grade 2 to 4 aGVHD, cGVHD, and overall survival (OS). aGVHD was present if graded 2 to 4 by cumulative incidence reported at 30, 60, and 100 days after transplantation.²⁵ cGVHD was reported as cumulative incidence at 6 months, 1 year, and 2 years after transplantation.^{26,27} The competing risk for aGVHD and cGVHD was death without GVHD. Patients were censored at date of subsequent transplant or date of last follow-up. OS was defined as time to death from any cause, with censoring at last follow-up.

Secondary end points included disease-free survival (DFS), transplant-related mortality (TRM), and relapse. DFS was defined as time to treatment failure (death or relapse). TRM was defined as any death within 28 days after transplantation or death in continuous remission, analyzed with relapse as a competing risk. Relapse was reported as cumulative incidence with TRM as a competing risk.

Statistical analysis

Univariable analysis. Donor, recipient, disease, and transplant-related factors were compared between parous female sibling and male URDs using the χ^2 test for categorical variables, and the Wilcoxon rank-sum test for continuous variables, with statistical significance set at $P < .01$ because of multiple comparisons. OS and DFS were estimated using the Kaplan-Meier method. Incidence of aGVHD, cGVHD, TRM, and relapse were estimated using cumulative incidence models with competing risks. Variables included the main effect of donor type (parous female sibling vs male URD), as well as other donor-related variables (age, ABO match, CMV serology). Additional variables included those that were patient related (age, sex, race, Karnofsky performance status); disease-related (disease type, disease stage at time of transplant); and transplant-related (time from diagnosis to transplant, graft source, conditioning regimen, GVHD prophylaxis, year of transplant). Disease stage was defined as early (first complete remission for AML and ALL; refractory anemia [RA] or RA with ringed sideroblasts or pretransplant BM blasts $<5\%$ for MDS), intermediate (second or greater complete remission for AML and ALL), or advanced (relapsed, primary refractory disease for AML and ALL; RA with excess blasts, or BM blasts $\geq 5\%$ for MDS). There were no interactions between donor type and any covariables.

Multivariable analysis. Multivariable Cox proportional hazards regression was used to control for potentially confounding clinical variables. Each variable was tested for the proportional hazard assumption. If the assumption was violated, the variable was included as a time-dependent variable. We assessed the significance of donor type (parous female sibling and male URD) on aGVHD, cGVHD, OS, DFS, TRM, and relapse by forcing this variable into the models. To identify significant risk factors, stepwise forward selection with a threshold of $P = .01$ was used for entry and retention in the model. Interactions were tested between the donor type and other significant covariables, and no interactions were identified. SAS version 9.4 (SAS Institute, Cary, NC) was used for the analyses.

Results

Patient characteristics

We identified 2813 patients in the CIBMTR registry who met the inclusion criteria and had complete information on donor sex and parity (parous female sibling donor = 892, male URD = 1921). Race categories are reported to the CIBMTR as white, African American, Asian/Pacific Islander, other, or missing. There were small numbers of African American (2%), Asian/Pacific-Islander (4%), and other/missing (4%), so these were pooled into a single, nonwhite group. All male URDs were high-resolution matched at HLA-A, B, C, and DRB1, and the majority were also matched at HLA-DQB1 (89%), but mismatched for HLA-DPB1 (64%).

There was no difference in median age between the 2 recipient cohorts, although a smaller proportion of parous female sibling recipients were >60 years (14% vs 21%). Donor age was higher in the parous female sibling group (48 vs 32 years, $P < .001$). There were significantly more PBSC grafts in the parous female sibling group (87% vs 76%, $P < .001$). A majority of patients were transplanted with early stage disease. The median time from

Table 1. Recipient characteristics

Variable	Parous sibling	Male URD	P
Number of patients	892	1921	
Age at transplant, median (range), y	49 (25-76)	50 (25-75)	.15
Age at transplant, n (%), y			<.001
25-39	202 (23)	484 (25)	
40-49	264 (30)	464 (24)	
50-59	297 (33)	566 (29)	
≥ 60	129 (14)	407 (21)	
Sex, n (%)			.07
Male	481 (54)	1107 (58)	
Female	411 (46)	814 (42)	
Race, n (%)			<.001
White	742 (83)	1795 (93)	
Nonwhite	131 (15)	98 (5)	
Missing	19 (2)	28 (1)	
Karnofsky score prior to HCT (%)			.73
$<90\%$	304 (34)	631 (33)	
$\geq 90\%$	563 (63)	1138 (59)	
Missing	25 (3)	152 (8)	
Disease, n (%)			.94
AML	553 (62)	1184 (62)	
ALL	160 (18)	341 (18)	
MDS	179 (20)	396 (21)	
Disease status at HCT, n (%)			<.001
Early	540 (60)	1000 (52)	
Intermediate	116 (13)	357 (19)	
Advanced	228 (26)	553 (29)	
Missing	8 (<1)	11 (<1)	

diagnosis to transplant differed between the 2 groups (parous female sibling: 5 months, male URD: 7 months; $P < .001$). Median follow-up of survivors was 66 months (range 3-170) for parous female sibling recipients and 72 months (range 3-169) for male URD recipients, $P < .001$ (Tables 1-3).

aGVHD

There was an increased risk of grade 2 to 4 aGVHD in recipients of male URD grafts as compared with recipients of parous female sibling donor grafts (100-day grade 2-4 aGVHD 46% in patients receiving male URD grafts vs 35% in those receiving parous female sibling grafts). This finding persisted in multivariable analysis (relative risk [RR] = 1.56, $P < .0001$) (Figure 1). Other significant covariables associated with grade 2 to 4 aGVHD included GVHD prophylaxis (tacrolimus/methotrexate lowest risk, $P = .0019$) and graft source (PBSC higher risk, RR = 1.32, $P = .0003$). Recipients of male URD grafts may also have experienced a higher risk of grade 3 to 4 aGVHD as compared with recipients of parous female sibling donor grafts, but this finding did not reach statistical significance given our conservative P value cutoff (RR = 1.27, $P = .016$) (Table 4).

Table 2. Donor characteristics

Variable	Parous sibling	Male URD	P
Donor age, median (range), y	48 (3-82)	32 (18-61)	<.001
Donor age, n (%), y			<.001
18-19	1 (<1)	52 (3)	
20-29	35 (4)	750 (39)	
30-39	180 (20)	651 (34)	
40-49	284 (32)	380 (20)	
50-59	252 (28)	83 (4)	
≥60	136 (15)	2 (<1)	
Missing	4 (<1)	3 (<1)	
D/R CMV serologic status, n (%)			<.001
−/−	149 (17)	605 (31)	
−/+	157 (18)	713 (37)	
+/−	122 (14)	158 (8)	
+/+	439 (49)	365 (19)	
Missing	25 (3)	80 (4)	
D/R ABO match, n (%)			<.001
Matched	580 (65)	859 (45)	
Minor mismatch	128 (14)	459 (24)	
Major mismatch	135 (15)	450 (23)	
Bidirectional mismatch	40 (4)	147 (8)	
Missing	9 (1)	6 (<1)	
Number of prior pregnancies in female donors, n (%)			N/A
1	137 (15)	0	
2	277 (31)	0	
3	185 (21)	0	
≥4	175 (20)	0	
Missing	118 (13)	0	

D/R, donor/recipient; N/A, not applicable.

cGVHD

At 6 months and 1 year posttransplantation, there was no difference in incidence of cGVHD among male URD recipients (33% and 50%, respectively) as compared with parous female sibling recipients (30% and 50%, respectively). We found that recipient sex was a significant covariable in the cGVHD multivariable model, so this model was adjusted to include a combination of donor type and recipient sex as the main effect. For male recipients, the risk of cGVHD was similar between donor types (34% for each donor type, $P = .89$ at 6 months, and 55% for parous female sibling donor vs 51% for male URDs, $P = .09$ at 12 months; RR = 1.09, $P = .23$). However, female recipients receiving male URD grafts experienced higher risks of cGVHD at 6 months posttransplant (31% as compared with 24% in female recipients receiving parous female sibling donor grafts, $P = .01$). By 1 year posttransplant, this difference was no longer statistically significant (50% of females receiving male URD grafts experienced cGVHD as compared with 44% of females receiving parous female sibling grafts, $P = .07$). In multivariable analysis, for female patients, male URDs conferred an adjusted relative risk of cGVHD of 1.43 ($P < .0001$) compared with

Table 3. HCT characteristics

Variable	Parous sibling	Male URD	P
Time from diagnosis to transplant, median (range), mo	5 (<1-153)	7 (<1-291)	<.001
Time from diagnosis to transplant, n (%), mo			<.001
<6	492 (55)	821 (43)	
6-12	197 (22)	522 (27)	
>12	203 (23)	574 (30)	
Missing	0	4 (<1)	
Graft type, n (%)			<.001
BM	118 (13)	462 (24)	
Peripheral blood	774 (87)	1459 (76)	
Conditioning regimen intensity, n (%)			.38
Myeloablative	673 (75)	1403 (73)	
TBI	341 (51)	685 (49)	
No TBI	332 (49)	718 (51)	
Reduced intensity	165 (18)	385 (20)	
TBI	31 (19)	67 (17)	
No TBI	134 (81)	318 (83)	
Nonmyeloablative	54 (6)	133 (7)	
TBI	51 (95)	122 (92)	
No TBI	3 (5)	11 (8)	
GVHD prophylaxis, n (%)			<.001
Tac + MTX	266 (30)	834 (43)	
Tac + MTX + others	29 (3)	176 (9)	
Tac ± others	121 (14)	365 (19)	
CsA + MTX	310 (35)	278 (14)	
CsA ± others	128 (14)	191 (10)	
Others*	36 (4)	76 (4)	
Missing	2 (<1)	1 (<1)	
Year of transplant, n (%)			<.001
2000-2003	255 (29)	317 (17)	
2004-2008	375 (42)	1119 (58)	
2009-2012	262 (29)	485 (25)	

CsA, cyclosporine; MMF, mycophenolate mofetil; MTX, methotrexate; Tac, tacrolimus; TBI, total body irradiation.

*Tac + CsA + MTX (n = 32), posttransplant cyclophosphamide (n = 25), Tac + CsA + MTX + MMF (n = 13), Tac + CsA + MMF (n = 12), Tac + CsA + MTX + others (n = 6), Tac + CsA + MMF + others (n = 2), Tac + CsA + others (n = 7), MTX + others (n = 5), MTX (n = 2), MMF (n = 3), MMF + others (n = 3), Siro (n = 1), steroids (n = 1).

those receiving parous female sibling grafts. Other significant covariables included year of transplant, with cGVHD more frequently seen in earlier transplant years (overall $P = .002$), and receipt of peripheral blood grafts (RR = 1.73 compared with BM, $P < .0001$) (Table 4). In male patients, donor type did not significantly impact cGVHD (Figure 2).

OS

A smaller percentage of male URD recipients were alive at 100 days (82% vs 88% of recipients of parous female sibling transplants, $P < .001$). However, by 1 year, this difference disappeared (Figure 3).




Figure 1. Cumulative incidence of grade 2 to 4 aGVHD by donor type.

In multivariable analysis, this small decrement in OS in recipients of male URD donor grafts persisted, although it no longer reached statistical significance (male URD RR = 1.10; 99% CI, 0.99-1.26; $P = .07$). Other variables associated with poorer OS included older

age, poorer Karnofsky score, advanced disease status at transplant, and earlier year of transplant (Table 5). Cause of death was largely because of primary disease and was similar between the 2 groups (parous female sibling 41%, male URD 44%). Six percent of deaths in both the parous female sibling and male URD groups were attributable to aGVHD. A comparable incidence of death attributed to cGVHD was seen in the 2 groups.

Secondary end points

DFS. DFS was inferior in the male URD cohort at 100 days (male URD 73% vs parous female sibling 78%, $P = .003$) and at 6 months (60% vs 65%, respectively, $P = .008$) posttransplantation. At 1 year and beyond, however, there was no significant difference in DFS: 1-year male URD 49% vs parous female sibling 54% ($P = .03$), 2-year male URD 41% vs parous female sibling 44% ($P = .19$), 3-year male URD 37% vs parous female sibling 39% ($P = .49$), and 5-year male URD 33% vs parous sibling 34% ($P = .52$). In multivariable analysis, donor type was not associated with DFS ($P = .449$). Older patient age, poorer Karnofsky score, TBI-based conditioning, advanced disease, longer time from diagnosis to

Table 4. GVHD outcomes

aGVHD variable	aGVHD 2-4				aGVHD 3-4			
	n	RR	99% CI	P	n	RR	99% CI	P
Donor group (main effect)								
Parous sibling	880	1.00			880	1.00		
Male unrelated	1908	1.56	1.31-1.85	<.0001	1908	1.27	0.98-1.64	.016
GVHD prophylaxis				.002				.0002
Tac + MTX	1094	1.00			1094	1.00		
Tac + MTX + others	202	1.12	0.65-1.18	.258	202	1.12	0.72-1.74	.502
Tac ± others	480	1.11	0.84-1.28	.632	480	1.11	0.80-1.53	.410
CsA + MTX	583	0.92	0.80-1.23	.960	583	0.92	0.66-1.28	.500
CsA ± others	315	1.75	1.09-1.72	.0001	315	1.75	1.26-2.43	<.0001
Others	112	1.20	0.91-1.86	.062	112	1.20	0.69-2.10	.389
Graft source								
BM	578	1.00			—	—	—	—
PB	2213	1.32	1.08-1.61	.0003	—	—	—	—
cGVHD variable	All donor/recipient pairs				Male recipients only			
	n	RR	99% CI	P	n	RR	99% CI	P
Donor/recipient pair (main effect)								
Parous sibling to female	405	1.00						
Parous sibling to male	474	1.39	1.09-1.78	.001	474	1.00		
Male unrelated to female	799	1.43	1.14-1.80	<.0001				
Male unrelated to male	1099	1.52	1.22-1.89	<.0001	1099	1.09	0.90-1.32	.231
Year of transplant				.002				ns
2000-2003	564	1.00						
2004-2008	1471	1.06	0.88-1.29	.381				
2009-2012	742	0.86	0.70-1.06	.064				
Graft source								
BM	574	1			327	1.00		
PB	2203	1.73	1.43-2.08	<.0001	1246	1.56	1.23-2.08	<.0001

CI, confidence interval; parous sibling, parous sibling donor; PB, peripheral blood; ns, not significant.




Figure 2. Cumulative incidence of cGVHD by donor type and recipient sex. (A) Male recipients. (B) Female recipients.

transplant, and earlier year of transplant were associated with poorer DFS (Table 6).

Relapse. There was no significant difference in incidence of relapse between the 2 donor cohorts at any time post-transplantation ($P = .59$). The increased risk of GVHD was not offset by lower relapse rate: in multivariable analysis, the relative risk of relapse in male URD recipients was 1.03 ($P = .61$). Significant variables associated with relapse included older age of the patient, AML diagnosis (vs MDS), and advanced disease status (Table 6).




Figure 3. OS survival by donor type.

Table 5. Cox regression for OS

Variable	N	HR	99% CI	P
Donor group (main effect)				
Parous sibling	892	1.00		
Male unrelated	1921	1.10	0.96-1.26	.070
Age at transplant, y				
25-39 (ref)	686	1.00		<.0001
40-49	728	1.20	1.00-1.43	.010
50-59	863	1.43	1.21-1.70	<.0001
60+	536	1.61	1.33-1.95	<.0001
Karnofsky score at transplant				
≥90 (ref)	1701	1.00		<.0001
<90	935	1.36	1.20-1.55	<.0001
Missing	177	1.03	0.81-1.33	.724
Disease status at transplant				
Early (ref)	1540	1.00		
Intermediate	473	1.11	0.93-1.32	.119
Advanced	781	1.82	1.59-2.08	<.0001
Missing	19	1.90	0.99-3.66	.011
Year of transplant				
2000-2003 (ref)	572	1.00		<.0001
2004-2008	1494	0.96	0.82-1.13	.523
2009-2012	747	0.76	0.63-0.92	<.001

HR, hazard ratio; ref, reference value.

TRM. TRM was greater in recipients of male URD grafts at 100 days (11% vs 8%, $P = .003$). However, at 6 months and beyond, incidence of TRM was not significantly different between the 2 cohorts. In multivariable analysis, donor type was not significantly predictive of TRM, but older age, poorer Karnofsky score, TBI-based conditioning, and earlier year of transplant were associated with higher TRM (Table 6).

Discussion

We undertook this analysis to provide guidance to transplant clinicians when the only available sibling donor is a sister with previous pregnancies, as these donors are known to confer an increased risk of aGVHD and cGVHD when compared with male siblings. We sought to answer the question, would unrelated male donors be preferable to parous female siblings? We found that after adjusting for other significant covariables, recipients of male URD grafts experienced a 56% higher risk of grade 2 to 4 aGVHD compared with recipients of parous female sibling grafts. Although parous female siblings more frequently donated PBSC, a product known to increase cGVHD, the effect was preserved even when controlling for this variable.²⁸ When evaluating only the most severe aGVHD (grade 3 to 4) this increased risk may have persisted, but our results no longer demonstrated statistical significance, possibly because of a relatively low incidence of severe aGVHD in the study sample. The increased early TRM in the male URD group may be attributable in part to the higher incidence of aGVHD. However, over time, TRM and OS were not significantly impacted by donor source in our multivariable

Table 6. Multivariable analyses for DFS, TRM, and relapse

Variable	DFS				TRM			Relapse		
	N	RR	99% CI	P	RR	99% CI	P	RR	99% CI	P
Donor group (main effect)										
Parous sibling (ref)	852	1.00			1.00			1.00		
Male URD	1901	1.04	0.91-1.19	.449	1.07	0.88-1.31	.380	1.03	0.87-1.23	.610
Age at transplant, y				<.0001			<.0001			<.0001
25-39 (ref)	669	1.00			1.00			1.00		
40-49	710	1.17	0.98-1.40	.022	1.32	1.01-1.74	.009	1.09	0.86-1.37	.360
50-59	848	1.39	1.170-1.64	<.0001	1.67	1.29-2.17	<.0001	1.27	1.02-1.58	.006
60+	526	1.66	1.37-2.00	<.0001	2.05	1.53-2.75	<.0001	1.53	1.19-1.96	<.0001
Disease										<.0001
AML (ref)	1701	–	–	–	–	–	–	1.00		
ALL	490	–	–	–	–	–	–	0.97	0.77-1.21	.708
MDS	562	–	–	–	–	–	–	0.62	0.49-0.77	<.0001
Karnofsky score at transplant				<.0001						
≥90 (ref)	1662	1.00			1.00			–	–	–
<90	917	1.31	1.15-1.48	<.0001	1.59	1.31-1.92	<.0001	–	–	–
Missing	174	1.10	0.86-1.41	.308	1.11	0.75-1.63	.487	–	–	–
TBI used in conditioning regimen										
TBI ± others (ref)	1277	1.00			1.00			–	–	–
Non-TBI	1476	0.86	0.76-0.97	.002	0.83	0.69-0.99	.008	–	–	–
Disease status at transplant				<.0001						<.0001
Early (ref)	1509	1.00			–	–	–	1.00		
Intermediate	466	1.06	0.890-1.26	.407	–	–	–	1.12	0.89-1.42	.198
Advanced	760	1.87	1.63-2.14	<.0001	–	–	–	2.57	2.15-3.06	<.0001
Missing	18	1.81	0.92-3.56	.023	–	–	–	2.73	1.24-6.02	.001
Year of transplant				.005			.002			
2000-2003 (ref)	544	1.00			1.00			–	–	–
2004-2008	1464	0.96	0.82-1.13	.534	0.85	0.68-1.08	.077	–	–	–
2009-2012	745	0.82	0.68-0.98	.004	0.68	0.52-0.90	<.001	–	–	–
Time from diagnosis to transplant, mo							.0054			
<6 (ref)	1286	–	–	–	1.00			–	–	–
6-12	702	–	–	–	1.35	1.08-1.68	.0004	–	–	–
>12	761	–	–	–	1.10	0.88-1.37	.2842	–	–	–
Missing	4	–	–	–	1.44	0.11-19	.7165	–	–	–

analyses, suggesting that the impact of aGVHD on these outcomes occurs early posttransplantation and may be counterbalanced by other factors posttransplant.

In contrast to aGVHD, the incidence of cGVHD varied not just by donor type, but also by sex of the recipient. We found that male recipients had equivalent rates of cGVHD regardless of donor type, whereas female recipients fared better with parous female sibling donors. Although prior work has focused on cGVHD in male recipients of female donor grafts, as female T cells recognize Y-chromosome encoded male-specific minor histocompatibility (H-Y) antigens,^{29,30} this study suggests that other minor histocompatibility antigen mismatches may be more important than H-Y mismatch. Why this effect was seen only in female recipients is unclear.

OS did not appear to be better among recipients of male URD grafts, possibly because TRM from cGVHD may have offset other benefits. Although some prior studies in URDs have found no association between parity and OS,²⁴ others have demonstrated poorer OS (and higher TRM) in male recipients of female grafts,³¹ and yet other analyses have shown improved OS.³² It is difficult to reconcile the marked differences in survival outcomes in the many studies that have evaluated donor sex or parity, but our large study suggests that if parity is a risk factor for GVHD or other poor outcomes, it is not as significant as the effects of receiving a graft from a URD. Like most transplant analyses, we confirmed that older patient age, poorer patient performance status, advanced disease, and earlier year of transplant were associated with poorer OS.²

We acknowledge limitations in our study. As with all registry studies, there may be miscategorization of the incidence of GVHD. Although we have information on degree of HLA match, this did not include data on killer-cell immunoglobulin-like receptor (*KIR*) gene complexes, which may affect early relapse and mortality.³³ Furthermore, we did not control for permissive and nonpermissive mismatching at DQB1 and DP. We did not evaluate the use of donor leukocyte infusions for relapsed disease in our analysis, which could impact the incidence of aGVHD and cGVHD, as well as relapse and OS. Our analysis was restricted to T-cell replete transplants, and hence our findings may not be extrapolated to patients receiving in vivo or ex vivo T-cell-depleted transplants. This is particularly relevant given our primary end points of aGVHD and cGVHD.^{34,35} Finally, as in all studies analyzing donor parity, we recognize that documentation of parity may be unreliable and subject to misclassification bias. However, if a nulliparous female donor were miscategorized as parous, we expect that this would bias the results toward the null.

In conclusion, compared with parous female sibling donors, male URDs imparted an increased risk of grade 2 to 4 aGVHD to all recipients, an increased risk of cGVHD to female recipients, and an equivalent risk of cGVHD to male recipients. This finding suggests that other minor histocompatibility antigen mismatches outweigh the impact of H-Y mismatch. Donor type does not impact long-term OS. When faced with a choice of an unrelated male donor or a parous female sibling donor, physicians should favor HLA-identical sibling donors irrespective of donor sex and parity in order to reduce the risk of aGVHD and cGVHD.

Acknowledgments

The authors thank the CIBMTR for data collection and analysis.

The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute, National Heart, Lung, and Blood Institute, and National Institute of Allergy and Infectious Diseases, National Institutes of Health; a Grant/Cooperative Agreement 4U10HL069294 from National Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health; a contract (HSH250201200016C) with Health Resources and Services Administration/Department of Health and Human Services; 2 grants (N00014-17-1-2388 and N00014-16-1-2020) from the Office of Naval Research; and grants from (asterisk indicates corporate members) *Actinium Pharmaceuticals Inc., *Amgen Inc., *Amneal Biosciences, *Angiocrine Bioscience Inc., an anonymous donation to the Medical College of Wisconsin, Astellas Pharma US, Atara

Biotherapeutics Inc., Be the Match Foundation, *Bluebird Bio Inc., *Bristol Myers Squibb Oncology, *Celgene Corporation, Cerus Corporation, *Chimerix Inc., Fred Hutchinson Cancer Research Center, Gamida Cell Ltd., Gilead Sciences Inc., HistoGenetics Inc., Immucor, *Incyte Corporation, Janssen Scientific Affairs LLC, *Jazz Pharmaceuticals Inc., Juno Therapeutics, Karyopharm Therapeutics Inc., Kite Pharma Inc., Medac GmbH, MedImmune, The Medical College of Wisconsin, *Merck & Co Inc., *Mesoblast, MesoScale Diagnostics Inc., Millennium (the Takeda Oncology Co.), *Milenyi Biotech Inc., National Marrow Donor Program, *Neovii Biotech NA Inc., Novartis Pharmaceuticals Corporation, Otsuka Pharmaceutical Co. Ltd. – Japan, PCORI, *Pfizer Inc., *Pharmacocycles LLC, PIRCHE AG, *Sanofi Genzyme, *Seattle Genetics, Shire, Spectrum Pharmaceuticals Inc., St. Baldrick's Foundation, *Sunesis Pharmaceuticals Inc., Swedish Orphan Biovitrum Inc., Takeda Oncology, Telomere Diagnostics Inc., and University of Minnesota.

The views expressed in this article do not reflect the official policy or position of the National Institutes of Health, the Department of the Navy, the Department of Defense, the Health Resources and Services Administration, or any other agency of the US government.

Authorship

Contribution: A.J.K., S.K., M.T.H., M.A., S.R.S., and A.W.L. designed research; S.K. and M.T.H. collected data and performed statistical analysis; A.J.K., S.K., M.T.H., M.A., S.R.S., and A.W.L. interpreted data; A.J.K. drafted the manuscript; and S.K., M.T.H., M.A., S.R.S., J.A.P., D.R.C., A.M.A., M.D.A., J.-Y.C., M.S.C., C.S.C., S.F., R.P.G., U.G., G.A.H., B.K.H., S.K.H., Y.I., R.T.K., M.A.K.-D., M.L.M., N.S.M., D.I.M., H.N., M.N., M.Q., O.R., H.C.S., K.R.S., M.M.S., T.T., A.U.-I., L.F.V., and A.W.L. critically reviewed and revised the manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for S.K.H. is Department of Oncology, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.

The current affiliation for Y.I. is National Cancer Center Hospital, Tokyo, Japan.

The current affiliation for M.A.K.-D. is Mayo Clinic Florida, Jacksonville, FL.

Correspondence: Anita J. Kumar, Tufts Medical Center, 800 Washington St, Box #245, Boston, MA 02111; e-mail: ajkumar@alum.mit.edu.

References

1. Kanda J, Ichinohe T, Matsuo K, et al. Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies: IPD-based meta-analysis of cohort studies. *Transfusion*. 2009;49(4):624-635.
2. Kollman C, Spellman SR, Zhang MJ, et al. The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. *Blood*. 2016;127(2):260-267.
3. Schmidt-Hieber M, Labopin M, Beelen D, et al. CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT. *Blood*. 2013;122(19):3359-3364.
4. Gupta V, Tallman MS, He W, et al. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. *Blood*. 2010;116(11):1839-1848.
5. Moore J, Nivison-Smith I, Goh K, et al. Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia. *Biol Blood Marrow Transplant*. 2007;13(5):601-607.

6. Robin M, Porcher R, Adès L, et al. Matched unrelated or matched sibling donors result in comparable outcomes after non-myeloablative HSCT in patients with AML or MDS. *Bone Marrow Transplant*. 2013;48(10):1296-1301.
7. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. *Blood*. 2012;119(17):3908-3916.
8. Schetelig J, Bornhäuser M, Schmid C, et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German Transplant Study Group. *J Clin Oncol*. 2008;26(32):5183-5191.
9. Ruggeri A, Battipaglia G, Labopin M, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. *J Hematol Oncol*. 2016;9:89.
10. Brissot E, Labopin M, Stelljes M, et al. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. *J Hematol Oncol*. 2017;10:130.
11. Warlick ED, Peffault de Latour R, Shanley R, et al. Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type. *Biol Blood Marrow Transplant*. 2015;21(2):357-363.
12. Servais S, Porcher R, Xhaard A, et al. Pre-transplant prognostic factors of long-term survival after allogeneic peripheral blood stem cell transplantation with matched related/unrelated donors. *Haematologica*. 2014;99(3):519-526.
13. Saber W, Cutler CS, Nakamura R, et al. Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). *Blood*. 2013;122(11):1974-1982.
14. Yakoub-Agha I, Mesnil F, Kuentz M, et al; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. *J Clin Oncol*. 2006;24(36):5695-5702.
15. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. *Bone Marrow Transplant*. 1998;22(8):755-761.
16. Gale RP, Bortin MM, van Bekkum DW, et al. Risk factors for acute graft-versus-host disease. *Br J Haematol*. 1987;67(4):397-406.
17. Kim HT, Zhang M-J, Woolfrey AE, et al. Donor and recipient sex in allogeneic stem cell transplantation: what really matters. *Haematologica*. 2016;101(10):1260-1266.
18. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. *Blood*. 1992;80(7):1838-1845.
19. Flowers ME, Pepe MS, Longton G, et al. Previous donor pregnancy as a risk factor for acute graft-versus-host disease in patients with aplastic anaemia treated by allogeneic marrow transplantation. *Br J Haematol*. 1990;74(4):492-496.
20. Kongtim P, Di Stasi A, Rondon G, et al. Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation? *Biol Blood Marrow Transplant*. 2015;21(4):713-719.
21. Loren AW, Bunin GR, Boudreau C, et al. Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2006;12(7):758-769.
22. Randolph SS, Gooley TA, Warren EH, Appelbaum FR, Riddell SR. Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants. *Blood*. 2004;103(1):347-352.
23. Remberger M, Kumlien G, Aschan J, et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2002;8(12):674-682.
24. Lee SJ, Klein J, Haagenson M, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. *Blood*. 2007;110(13):4576-4583.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant*. 1995;15(6):825-828.
26. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. *Blood*. 2002;100(2):406-414.
27. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. *Am J Med*. 1980;69(2):204-217.
28. Bacigalupo A, Socié G, Schrezenmeier H, et al; Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT). Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups. *Haematologica*. 2012;97(8):1142-1148.
29. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. *Blood*. 2005;105(7):2973-2978.
30. Goulmy E, Termijtelen A, Bradley BA, van Rood JJ. Alloimmunity to human H-Y. *Lancet*. 1976;2(7996):1206.
31. Gratwohl A, Stern M, Brand R, et al; European Group for Blood and Marrow Transplantation and the European Leukemia Net. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. *Cancer*. 2009;115(20):4715-4726.
32. Farham S, Peres E, Pelland D, et al. Impact of gender: female matched related donor versus male matched unrelated donor on peripheral blood allogeneic stem cell transplant for male recipients [abstract]. *Biol Blood Marrow Transplant*. 2015;21(2, suppl):S281-S282. Abstract 401.

33. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1. *N Engl J Med*. 2012; 367(9):805-816.
34. Pavletic SZ, Carter SL, Kernan NA, et al; National Heart, Lung, and Blood Institute Unrelated Donor Marrow Transplantation Trial. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. *Blood*. 2005;106(9): 3308-3313.
35. Wagner JE, Thompson JS, Carter SL, Kernan NA; Unrelated Donor Marrow Transplantation Trial. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. *Lancet*. 2005; 366(9487):733-741.